Conduit Pharmaceuticals to Acquire 03 Life Sciences
Ticker: CDTTW · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Feb 11, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50, $600,000, $1.7 million, $2,650,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, oncology, pipeline
TL;DR
Conduit Pharma buying 03 Life Sciences to boost oncology pipeline. Deal expected Q2 2025.
AI Summary
Conduit Pharmaceuticals Inc. announced on February 7, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of common stock of 03 Life Sciences. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions. This acquisition aims to expand Conduit Pharmaceuticals' pipeline in the oncology sector.
Why It Matters
This acquisition could significantly bolster Conduit Pharmaceuticals' presence in the oncology market, potentially leading to new treatment options and increased market share.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks, including integration challenges, regulatory hurdles, and the possibility of not achieving projected synergies.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant and acquirer
- 03 Life Sciences (company) — Target company to be acquired
- February 7, 2025 (date) — Date of earliest event reported
- second quarter of 2025 (date) — Expected closing period for the acquisition
- Delaware (jurisdiction) — State of incorporation for Conduit Pharmaceuticals Inc.
- Murphy Canyon Acquisition Corp. (company) — Former company name of Conduit Pharmaceuticals Inc.
- November 30, 2021 (date) — Date of name change from Murphy Canyon Acquisition Corp.
FAQ
What is the primary strategic goal of Conduit Pharmaceuticals Inc. in acquiring 03 Life Sciences?
The acquisition is intended to expand Conduit Pharmaceuticals' pipeline in the oncology sector.
When is the acquisition of 03 Life Sciences expected to be completed?
The transaction is expected to close in the second quarter of 2025.
What are the conditions for the closing of the acquisition?
The closing is subject to customary closing conditions.
What was the former name of Conduit Pharmaceuticals Inc.?
The former name of Conduit Pharmaceuticals Inc. was Murphy Canyon Acquisition Corp.
On what date was the name change from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc. effective?
The date of the name change was November 30, 2021.
Filing Stats: 627 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2025-02-11 08:00:16
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
- $600,000 — below, in the full principal amount of $600,000 and, accordingly, satisfied all of its
- $1.7 million — has previously converted approximately $1.7 million of the original principal amount of $2,
- $2,650,000 — ion of the original principal amount of $2,650,000 under the Senior Note into shares of co
- $500,000 — al amount of $2,650,000, inclusive of a $500,000 original issuance discount. The Senior
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-25-005796.txt ( ) — 261KB
- cdt-20250207.xsd (EX-101.SCH) — 4KB
- cdt-20250207_def.xml (EX-101.DEF) — 29KB
- cdt-20250207_lab.xml (EX-101.LAB) — 36KB
- cdt-20250207_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CONDUIT PHARMACEUTICALS INC. February 11, 2025 By: /s/ David Tapolczay Name: David Tapolczay Title: Chief Executive Officer